A Phase 3 interventional study of ezetimibe and atorvastatin and atorvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-05-14.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 7th largest by enrollment of the 97 interventional ones that give a count, is one of 16 that started in 2007, is one of 50 in phase 3, and was the 20th registered.
1,179 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 16 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,053 is above the median of 109 across 978 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 97 interventional studies. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 14th largest by enrollment of the 81 interventional ones that give a count, is one of 13 that started in 2007, is one of 58 in phase 3, and was the 33rd registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, from their registry updates:
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A 12 week clinical trial in patients 65 years of age and older with hypercholesterolemia at high risk for coronary heart disease to study the effects of atorvastatin and ezetimibe given in combination and two higher doses of atorvastatin on lipid lowering.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ezetimibe and atorvastatin · Drug: Placebo (unspecified)
Drug: atorvastatin · Drug: Placebo (unspecified)
Drug pages: Ezetimibe · Atorvastatin
ezetimibe 10 mg and atorvastatin 10 mg daily for 12 weeks
Atorvastatin 20 mg daily for 6 weeks, and up-titrated to atorvastatin 40 mg daily for an additional 6 weeks
Placebo (unspecified) daily for 12 weeks
Percent Change From Baseline in LDL-C at Week 6
Time frame: Baseline and Week 6
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12
Time frame: Baseline and Week 12
Number of Patients Who Achieved Low Density Lipoprotein Cholesterol (LDL-C) <70 mg/dL at Week 6
Time frame: Week 6
Number of Patients Who Achieved Low Density Lipoprotein Cholesterol (LDL-C) <70 mg/dL at Week 12
Time frame: Week 12
Number of Patients Who Achieved LDL-C <100 mg/dL for Patients Without Atherosclerotic Vascular Disease (AVD) and LDL-C <70 mg/dL for Patients With Atherosclerotic Vascular Disease (AVD) at Week 6
Time frame: Week 6
Number of Patients Who Achieved LDL-C<100 mg/dL for Patients Without AVD and LDL-C<70 mg/dL for Patients With AVD at Week 12
Time frame: Week 12
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 6
Time frame: Baseline and Week 6
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6
Time frame: Baseline and Week 6
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
Time frame: Baseine and Week 12
Percent Change From Baseline in Total Cholesterol (TC) at Week 6
Time frame: Baseline and Week 6
Percent Change From Baseline in Total Cholesterol (TC) at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Triglycerides (TG) at Week 6
Time frame: Baseline and Week 6
Percent Change From Baseline in Triglycerides (TG) at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 6
Time frame: Baseline and Week 6
Percent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 6
Time frame: Baseline and Week 6
Percent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Total Cholesterol (TC): High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
Time frame: Baseline and Week 6
Percent Change From Baseline in Total Cholesterol (TC):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
Time frame: Baseline and Week 6
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 6
Time frame: Baseline and Week 6
Percent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
Time frame: Baseline and Week 6
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 6
Time frame: Baseline and Week 6
Percent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 12
Time frame: Baseline and Week 12
Phase III First Patient In: 28-Feb-2007; Last Patient Last Visit: 01-Oct-2008 143 centers worldwide (United States, Canada, Poland, Romania, Ukraine and Russia)
| Milestone | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Started | 526 | 527 |
| Completed | 503 | 507 |
| Not completed | 23 | 20 |
| Withdrew: Adverse event | 16 | 9 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol violation | 4 | 3 |
| Withdrew: Withdrawal by subject | 3 | 7 |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in LDL-C at Week 6 | -26.7 (-28.6 to -24.7) | -12.8 (-14.8 to -10.9) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 | -22.5 (-25.0 to -19.9) | -17.9 (-20.5 to -15.4) |
| Participants | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| <70 mg/dL | 244 | 92 |
| ≥70 mg/dL | 271 | 423 |
| Participants | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| <70 mg/dL | 225 | 164 |
| ≥70 mg/dL | 291 | 345 |
| Participants | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| <100 mg/dL (w/o AVD) and <70 mg/dL (w/ AVD) | 274 | 127 |
| >100 mg/dL (w/o AVD) and ≥70 mg/dL (w/AVD) | 241 | 388 |
| Participants | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| <100 mg/dL (w/o AVD) and <70 mg/dL (w/ AVD) | 255 | 200 |
| ≥100 mg/dL (w/o AVD) and ≥70 mg/dL (w/ AVD) | 261 | 309 |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 6 | 2.5 (1.1 to 4.0) | 0.7 (-0.8 to 2.1) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 | 2.4 (0.9 to 3.8) | -0.8 (-2.2 to 0.7) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6 | -23.5 (-25.2 to -21.7) | -11.2 (-13.0 to -9.5) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12 | -20.0 (-22.3 to -17.7) | -15.8 (-18.1 to -13.5) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (TC) at Week 6 | -15.9 (-17.2 to -14.6) | -8.0 (-9.3 to -6.7) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (TC) at Week 12 | -13.6 (-15.2 to -12.0) | -11.6 (-13.2 to -10.0) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Triglycerides (TG) at Week 6 | -12.9 (-14.3 to -9.7) | -5.7 (-8.4 to -3.5) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Triglycerides (TG) at Week 12 | -11.8 (-13.7 to -9.3) | -8.5 (-11.3 to -7.1) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 6 | -16.8 (-18.5 to -15.1) | -7.7 (-9.4 to -6.0) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 12 | -14.0 (-16.1 to -11.9) | -10.8 (-12.9 to -8.7) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 6 | -1.1 (-2.4 to 0.3) | -1.7 (-3.0 to -0.3) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 12 | 0.7 (-0.7 to 2.1) | -2.0 (-3.4 to -0.6) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (TC): High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6 | -16.9 (-18.4 to -15.3) | -7.9 (-9.4 to -6.3) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (TC):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12 | -14.4 (-16.4 to -12.5) | -9.8 (-11.8 to -7.9) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6 | -27.2 (-29.5 to -25.0) | -12.6 (-14.9 to -10.4) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12 | -22.9 (-25.9 to -20.0) | -16.0 (-18.9 to -13.1) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 6 | -14.8 (-16.6 to -12.9) | -5.2 (-7.1 to -3.4) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 12 | -13.5 (-15.7 to -11.3) | -8.2 (-10.4 to -6.0) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6 | -24.0 (-26.2 to -21.8) | -11.1 (-13.3 to -8.9) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12 | -20.4 (-23.2 to -17.6) | -13.8 (-16.6 to -10.9) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 6 | -13.5 (-19.6 to -6.8) | -10.7 (-17.0 to -3.9) |
| Percent Change | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Percent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 12 | -21.7 (-27.3 to -15.6) | -14.6 (-20.7 to -8.0) |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atorva 10 mg + EZ | — | — | — |
| Atorva 20 mg / Atorva 40 mg | — | — | — |
| Event | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| Angina pectorisCardiac disorders | 1/526 | 2/525 |
| Acute myocardial infarctionCardiac disorders | 1/526 | 1/525 |
| Angina unstableCardiac disorders | 0/526 | 1/525 |
| Coronary artery diseaseCardiac disorders | 0/526 | 1/525 |
| Myocardial infarctionCardiac disorders | 1/526 | 1/525 |
| Abdominal discomfortGastrointestinal disorders | 0/526 | 1/525 |
| Chest painGeneral disorders | 0/526 | 1/525 |
| GastroenteritisInfections and infestations | 0/526 | 1/525 |
| Brain stem haemorrhageNervous system disorders | 0/526 | 1/525 |
| DizzinessNervous system disorders | 0/526 | 1/525 |
| Event | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg |
|---|---|---|
| HypertensionVascular disorders | 0/526 | 9/525 |
| Upper respiratory tract infectionInfections and infestations | 7/526 | 8/525 |
| NasopharyngitisInfections and infestations | 6/526 | 7/525 |
| HeadacheNervous system disorders | 7/526 | 7/525 |
| ConstipationGastrointestinal disorders | 7/526 | 3/525 |
| Back painMusculoskeletal and connective tissue disorders | 4/526 | 6/525 |
| BronchitisInfections and infestations | 6/526 | 3/525 |
| Asparate aminotransferase increasedInvestigations | 2/526 | 5/525 |
| Muscle spasmMusculoskeletal and connective tissue disorders | 0/526 | 5/525 |
| Blood glucose increasedInvestigations | 5/526 | 2/525 |
| Age, Continuous(years) | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg | Total |
|---|---|---|---|
| Mean | 71.2 (65 to 86) | 71.2 (65 to 92) | 71.2 (65 to 92) |
| Sex: Female, Male(Participants) | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg | Total |
|---|---|---|---|
| Female | 277 | 286 | 563 |
| Male | 249 | 241 | 490 |
| Race/Ethnicity, Customized(Participants) | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg | Total |
|---|---|---|---|
| White | 503 | 505 | 1008 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Asian | 2 | 3 | 5 |
| Black | 21 | 17 | 38 |
| Multi-Racial | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg | Total |
|---|---|---|---|
| North America | 189 | 197 | 386 |
| Europe | 337 | 330 | 667 |
| BMI [Body Mass Index (<30, ≥30 kg/m2)](Participants) | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg | Total |
|---|---|---|---|
| <30 kg/m2 | 359 | 362 | 721 |
| ≥30 kg/m2 | 165 | 165 | 330 |
| Missing | 2 | 0 | 2 |
| Apo lipoprotein A-I (Apo A-I)(mg/dL) | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg | Total |
|---|---|---|---|
| Mean | 164.3 ± 28.7 | 164.4 ± 26.8 | 164.4 ± 27.7 |
| Apo lipoprotein B (Apo B)(mg/dL) | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg | Total |
|---|---|---|---|
| Mean | 103.6 ± 22.8 | 101.8 ± 21.4 | 102.7 ± 22.1 |
| Apo lipoprotein B (Apo B):Apo lipoprotein A-I (Apo A-I) Ratio(Ratio) | Atorva 10 mg + EZ | Atorva 20 mg / Atorva 40 mg | Total |
|---|---|---|---|
| Mean | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.6 ± 0.2 |
9 further baseline measures are reported on the registry.
No study locations are listed for this record.
Plan to share: No
The record gives a start of Jan 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2009, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ezetimibe · Atorvastatin